As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

New research explores the wide world of the positives, and potential drawbacks, of new obesity medications. And each brings a new consideration for physicians.

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Eli Lilly's profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly reported mixed fourth-quarter results on Thursday, surpassing earnings expectations but falling short of sales ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

Today, the market's average price-to-earnings (P/E) multiple is around 30.6. So stocks ... As the creator of the blockbuster weight-loss drug Zepbound, and the blockbuster type 2 diabetes drug ...

An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts ...

In the current Lexaria Study, the oral DehydraTECH-tirzepatide was conservatively dosed at only 56 times more tirzepatide than what is administered via an injected Zepbound® dose, meaning that ...